Risk Score to Predict Serious Bleeding in Stable Outpatients with or at Risk of Atherothrombosis by Ducrocq, Gregory et al.
Boston University
OpenBU http://open.bu.edu
Mathematics and Statistics CAS: Mathematics & Statistics: Scholarly Papers
2010-02-24
Risk Score to Predict Serious
Bleeding in Stable Outpatients with
or at Risk of Atherothrombosis
Ducrocq, Gregory, Joshua S. Wallace, Gabriel Baron, Philippe Ravaud, Mark J.
Alberts, Peter W.F. Wilson, Erik Magnus Ohman, Danielle M. Brennan, Ralph B.
D'Agostino, Deepak L. Bhatt, Philippe Gabriel Steg. "Risk Score to Predict Serious
Bleeding in Stable Outpatients with or at Risk of Atherothrombosis" European Heart
Journal 31(10): 1257-1265. (2010)
https://hdl.handle.net/2144/2797
Boston University
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
Prevention
Risk score to predict serious bleeding in stable
outpatients with or at risk of atherothrombosis
Gregory Ducrocq1*, Joshua S. Wallace2,3,4, Gabriel Baron2,3,4, Philippe Ravaud2,3,4,
Mark J. Alberts5, Peter W.F. Wilson6, Erik Magnus Ohman7, Danielle M. Brennan8,
Ralph B. D’Agostino9, Deepak L. Bhatt10, and Philippe Gabriel Steg1 on behalf of the
REACH Investigators†
1INSERM U-698 ‘Recherche Clinique en Athe´rothrombose’, Department of Cardiology, Centre Hospitalier Universitaire Bichat-Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex
18, France; 2AP-HP, Hoˆpital Bichat, De´partement d’Epide´miologie, Biostatistique et Recherche Clinique, Paris, France; 3INSERM, U738, Paris, France; 4Universite´ Paris 7 Denis Diderot, UFR
de Me´decine, Paris, France; 5Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 6Emory School of Medicine, Atlanta, GA, USA; 7Duke University, Durham, NC, USA;
8Cleveland Clinic, Cleveland, OH, USA; 9Boston University, Boston, MA, USA; and 10VA Boston Healthcare System and Brigham and Women’s Hospital, Boston, MA, USA
Received 11 September 2009; revised 30 November 2009; accepted 29 December 2009; online publish-ahead-of-print 24 February 2010
Aims To develop a risk score to quantify bleeding risk in outpatients with or at risk of atherothrombosis.
Methods
and results
We studied patients in the REACH Registry, a cohort of 68 236 patients with/at risk of atherothrombosis. The outcome
of interest was serious bleeding (non-fatal haemorrhagic stroke or bleeding leading to hospitalization and transfusion)
over 2 years. Risk factors for bleeding were assessed using modified regression analysis. Multiple potential scoring
systems based on the least complex models were constructed. Competing scores were compared on their discrimina-
tive ability via logistic regression. The score was validated externally using the CHARISMA population. From a final
cohort of 56 616 patients, 804 (1.42%, 95% confidence interval 1.32–1.52) experienced serious bleeding between base-
line and 2 years. A nine-item bleeding risk score (0–23 points) was constructed (age, peripheral arterial disease, con-
gestive heart failure, diabetes, hypertension, smoking, antiplatelets, oral anticoagulants, hypercholesterolaemia).
Observed incidence of bleeding at 2 years was: 0.46% (score 6); 0.95% (7–8); 1.25% (9–10); 2.76% (11). The
score’s discriminative performance was consistent in CHARISMA and REACH (c-statistics 0.64 and 0.68, respectively);
calibration in the CHARISMA population was very good (modified Hosmer-Lemeshow c2 ¼ 4.74; P ¼ 0.69).
Conclusion Bleeding risk increased substantially with a score .10. This score can assist clinicians in predicting the risk of serious
bleeding and making decisions on antithrombotic therapy in outpatients.
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Introduction
Antithrombotics are commonly used for the treatment and preven-
tion of ischaemic events in patients with established atherothrombosis
or with risk factors.1 Although effective, they increase the risk of
bleeding, which may negate their benefits. Indeed, bleeding events
are associated with worse short- and long-term outcomes.2,3
Prolonged or even lifetime antithrombotic therapy is becoming
commonplace. Coronary artery disease (CAD) patients are
treated with aspirin for life and, whenever an acute coronary syn-
drome occurs or a coronary stent is placed, undergo protracted
treatment with a thienopyridine in addition to aspirin. Before
embarking on such treatment, it is important to assess both the
benefits and the risks of these therapies. For example, guidelines
recommend continuing double antiplatelet therapy for over 12
months after implantation of a drug-eluting stent (DES) in patients
at low risk of bleeding.4 While multivariable modelling of bleeding
risk has been performed in outpatients with atherothrombosis in
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whom anticoagulant or antiplatelet therapy is considered,5 there is,
however, no tool to assess the long-term bleeding risk in clinical
practice. A score to quantify risk of bleeding would be helpful
for clinical decision-making, particularly if it allowed comparison
of the risks associated with use of antithrombotic therapy. This
could help clinicians select the proper treatment modality [coron-
ary artery bypass graft (CABG) vs. percutaneous coronary inter-
vention vs. medical therapy] and assist in the selection of stent
type (drug eluting vs. bare metal).
Methods
We studied patients enrolled in the Reduction of Atherothrombosis
for Continued Health (REACH) Registry,6 a prospective registry of
patients aged at least 45 years, with established cerebrovascular
disease (CVD), CAD, peripheral arterial disease (PAD), or with at
least three atherosclerosis risk factors. The design of the REACH Reg-
istry has been described.6 In brief, the REACH Registry is an observa-
tional registry designed to provide clinical follow-up of 68 236
outpatients from 44 countries in North America, Latin America,
Western Europe, Eastern Europe, Middle East, Asia, and Australia.
Patients were enrolled over an initial 7 month recruitment period
(December 2003 to June 2004) on a worldwide basis. Data regarding
medical history, risk factors, characteristics, and management were col-
lected at baseline. Follow-up assessments tracked specified clinical
events at 12+ 3 and 21+ 3 months in all countries (yielding a
maximum follow-up of 24 months). In the USA, additional follow-up
took place at 6 and 18 months.6
This protocol was submitted to institutional review boards accord-
ing to local requirements and signed informed consent was required
for all patients.
Measures
The outcome of interest was an episode of serious bleeding, defined as
non-fatal haemorrhagic stroke or bleeding leading to both hospitaliz-
ation and transfusion. Events were recorded at each of the four
follow-up assessments. We created a binary outcome based on an
observation of at least one bleeding event, or no recorded bleeding
event as of the last available assessment. This outcome was designed
to provide a conservative estimate of bleeding events over the 2
year period. Bleeding episodes of lesser severity may have significant
impact for patients and their physicians, but are difficult to capture
reliably.
Risk factors
The 65 variables collected in the baseline case report form were ana-
lysed as potential predictors of bleeding. Demographic data included
age, sex, ethnicity, whether the patient lived alone, education, and
employment status. Age was categorized into 10 year intervals up to
75 years. Atherothrombotic risk factors were: advanced age (65
years in men, 70 in women), smoking, diabetes, diabetic nephropa-
thy, hypertension, hypercholesterolaemia, ankle brachial index (ABI)
,0.9, carotid stenosis, and carotid plaques.
History of ischaemic disease was divided into CVD (documented
transient ischaemic attack or ischaemic stroke); CAD (stable/unstable
angina, myocardial infarction, coronary angioplasty/stenting, and
CABG); and PAD (historic or current intermittent claudication associ-
ated with one of: ABI ,0.9, lower-limb arterial surgery, or lower-limb
amputation). For each, we also considered summary variables of CVD,
CAD, and PAD defined as including one of the variables described
earlier.
Physical measurements included weight, height, waist circumference,
blood pressure, and ABI. Body mass index (BMI) was classified into five
1 point intervals between 25 and 35 kg/m2; a separate binary variable
classifying patients as obese (BMI at least 30 kg/m2) was created.
Weight was categorized into 20 kg increments between 60 and
100 kg. Waist circumference was used to create a binary measure of
obesity using the National Cholesterol Education Program Adult
Treatment Panel III cut-off (at least 88 cm for women; at least 102
for men).7 Biochemical measurements included serum creatinine;
fasting blood glucose, total cholesterol, and triglycerides; and microal-
buminuria. Current or past medical conditions included carotid angio-
plasty/stenting, carotid surgery, congestive heart failure (CHF), atrial
fibrillation/flutter, aortic valve stenosis, abdominal aortic aneurysm,
diabetes, hypertension, and smoking status.
Current chronic therapies were categorized into three classes: cardi-
ovascular agents (calcium-channel antagonists, beta-blockers, nitrates/
other anti-anginal agents, diuretics, angiotensin-converting-enzyme
inhibitors, angiotensin II receptor blockers, other antihypertensives, per-
ipheral arterial claudication medications); antidiabetic agents (insulin,
biguanides, sulfonylureas, thiazolidinediones, other); non-steroidal
anti-inflammatory drugs; lipid-lowering drugs (statins or other); and
other medications with an antithrombotic or anticoagulant effect, such
as antiplatelets (aspirin or other) or oral anticoagulants. A four-category
summary variable was created for the two antiplatelet agents,
coding patients as using aspirin alone, another antiplatelet agent, both,
or neither.
From this initial pool of variables, we eliminated variables for which
data were missing in .5% of patients. There was no imputation for
these variables, which were diabetic nephropathy; ABI ,0.9; carotid
stenosis (asymptomatic); carotid plaques; intermittent claudication
associated with ABI ,0.9; ethnicity; education; waist-based obesity;
aortic valve stenosis; abdominal aortic aneurysm; and the biochemical
measurements.
Statistical analysis
The aim was to create a score for predicting risk of serious bleeding
that would be both easy to use and easy to calculate from routinely
available clinical data.
Using bleeding as the dichotomous outcome variable, we assessed
the univariate relationship between each factor and outcome. All vari-
ables were assessed using logistic regression analysis, with a selection
criterion of P, 0.05. The baseline category for qualitative variables
was either the lowest category (in the case of ordinal variables) or
the category containing the largest proportion of patients. To maxi-
mize the usable population size, the availability of data for .95% of
patients was also retained as a criterion for variable entry. The result-
ing list of potential factors was then further restricted according to
ease of assessment in a clinical setting and to their known association
with bleeding. Given the large number of variables, the overlap inter-
actions and correlations were not studied.
Multivariable analysis
Stepwise logistic regression produces highly variable results,8 even if
split or cross-validation is employed.9 We therefore chose a modified
regression technique employing multiple regressions on bootstrap
resamples.10,11 In essence, we generated multiple bootstrap samples
to which the same automatic selection techniques were applied. Selec-
tion of the final model was based on the resulting estimates of the dis-
tribution of the model selection process; in practice, the percentage of
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analyses in which the variables were selected.10 To generate parsimo-
nious models, we used Akaike’s Information Criterion for best-fit
model selection.
Using the resulting ordering of factors, we compared models for the
n-highest ranked factors. Discrimination was assessed by calculating
receiver operating characteristic (ROC) curves. To maximize the accu-
racy of the parameter estimates, the maximum possible sample size
was used for each logistic regression; in other words, all patients
with data for the selected factors.
We built multiple potential scoring systems based on the least
complex models, retaining similar discriminative capacity to that of
the full model. The scores were based on nearest integer approxi-
mations of constant multiples of the regression coefficients. Compet-
ing scores were compared for discriminative ability via logistic
regression.
External validation
External validation was carried out using the 15 603 patients enrolled
in the Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance (CHARISMA) trial.12 The
clinical characteristics of the CHARISMA trial and REACH Registry
populations were very similar.
In CHARISMA, the bleeding endpoint was based on the Global Util-
ization of Streptokinase and Tissue Plasminogen Activator for
Occluded Coronary Arteries (GUSTO) definition.13 For the validation,
we used a combination of severe and moderate bleeding. Severe
bleeding was defined as fatal bleeding, intracranial haemorrhage, or
bleeding causing haemodynamic compromise (requiring blood, fluid
replacement, inotropic support, or surgical intervention). Moderate
bleeding was defined as bleeding requiring blood transfusion but not
resulting in haemodynamic compromise.
Discrimination was assessed using c-statistics. Calibration was
assessed using quartile plots; mean predicted and observed risks; and
modified Hosmer–Lemeshow c2 statistics. We also calculated the
coefficient of contingency, which quantifies the lack of model fit adjust-
ing for the sample size.
Results
For the global registry of 68 236, follow-up rates were good: 93.3%
at 12 months and 75% at 21 months. A total of 65 441 (95.9%)
patients attended at least one follow-up assessment. We excluded
852 of these patients due to incomplete outcome data, yielding a
final sample size of 64 589 (94.7%). The mean age of the patient
population was 68.6 years and 36.2% were female. The patients’
other baseline characteristics are shown in Table 1. On those
64 589 patients, 903 serious bleeding events (1.4%) were
recorded. The details of the composite outcome are shown in
Table 2.
The population retained for the final multivariable analysis was a
subset of the study population (n ¼ 56 616; 87.7%) who had data
available for each of the 17 factors selected in the multivariable
analysis. In this final population, 804 serious bleeding were
recorded (804/56 616: 1.42%; confidence interval 1.32, 1.52).
Univariate factors
Based on univariate analyses of each of the 49 factors and bleeding,
we excluded the factors without relationship to the outcome of
interest (P . 0.05), including smoking, unstable angina, myocardial
infarction, coronary angioplasty/stenting, sex, formal education, the
two BMI factors, weight, systolic blood pressure, carotid angio-
plasty/stenting, three cardiovascular drugs (calcium-channel antag-
onists, beta-blockers, ACE-inhibitors), statins, other lipid-lowering
agents, at least one lipid-lowering agent, three antidiabetic agents
(biguanides, sulfonylureas, others), non-steroidal anti-inflammatory
drugs, and physician age.
The resulting potential factors were then further restricted
according to ease of assessment in a clinical setting, and the plausi-
bility of a causal association with bleeding (ethnic origin, height,
other antihypertensive drugs, other antidiabetic agents, and,
finally, physician specialty, practice type, and geographic location
were eliminated). This provided a list of 18 factors: four risk
factors (advanced age, type I or II diabetes, hypertension, hyperch-
olesterolaemia); four indications of ischaemic disease (CVD, stable
angina, CABG, PAD); three demographic factors (age, living alone
or not, employment status); four medical conditions (carotid
surgery, CHF, atrial fibrillation, smoking); and three medications
(antiplatelets, oral anticoagulants, diuretics). Advanced age as a
binary risk factor was not associated with the outcome when
age classes were accounted for (P. 0.5), and was therefore not
included separately in the following analyses. Estimates of the
relationships between risk of bleeding and the 17 remaining
factors are shown in Table 1.
Bootstrap regressions
The sample for the bootstrap regression was the subset of the
study population (n ¼ 56 616; 87.7%) with data available for all
17 of the selected factors. A total of 804 patients [1.42% (95% con-
fidence interval 1.32–1.52) of the bootstrap population], and 99
patients (1.2%) of the excluded population, had experienced at
least one bleeding event. The difference in bleeding rates
between patients with and without missing values was not signifi-
cant (P ¼ 0.22).
One thousand bootstrap samples were generated and analysed
according to backwards stepwise logistic regression, using the
Akaike Information Criterion as the stopping criterion. Five vari-
ables (age, antiplatelet agents, anticoagulants, hypertension,
smoking) were selected in .98% of the regression analyses.
Four more variables (CHF, diabetes, hypercholesterolaemia,
PAD) were selected in .85% of analyses. The variables CVD,
employment type, and CABG were selected in .60% of cases.
All other variables were selected in ,60% of the regressions.
The discriminative power for each of the logistic regressions on
ordered selections of the highest ranked n-factors, with n taking
values from 1 to 17 (full model), was assessed. The maximum
value of c-statistic (0.68) was obtained for the 15 factor model;
however, models with as few as nine variables (c-statistic ¼ 0.68)
showed no substantial reduction in discrimination.
Score construction
Four scores were created, containing 8–11 variables. Logistic
regression onto the score values produced very similar results in
terms of discrimination to the derivative models, hence the nine-
factor regression model was chosen (c-statistic ¼ 0.68) as the least
complex model that retained the majority of the predictive value.
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Table 1 Baseline characteristics of the population and univariate analysis of potential risk factors
Characteristic n (%) Haemorrhage, n (%) OR (95% CI) P-valuea
Yes No
Demographics/physical characteristics
Gender
Female 23 386 (36.2) 318 (35.2) 23 068 (36.2) 1 0.52
Male 41 155 (63.8) 585 (64.8) 40 570 (63.8) 1.05 (0.91–1.20)
Age, years
45–54 7231 (11.2) 45 (5.0) 7186 (11.3) 1 ,0.001
55–64 15 083 (23.4) 150 (16.6) 14 933 (23.5) 1.60 (1.15–2.24)
65–74 23 703 (36.8) 313 (34.7) 23 390 (36.8) 2.14 (1.56–2.92)
75þ 18 366 (28.5) 394 (43.7) 17 972 (28.3) 3.50 (2.57–4.77)
Lives alone
No 50 947 (80.0) 689 (77.0) 50 258 (80.0) 1 0.02
Yes 12 748 (20.0) 206 (23.0) 12 542 (20.0) 1.20 (1.02–1.40)
Employment status
Full time 10 718 (16.8) 95 (10.6) 10 623 (16.9) 0.54 (0.44–0.67) ,0.001
Part time 3786 (5.9) 49 (5.5) 3737 (5.9) 0.79 (0.59–1.06)
Unemployed 4267 (6.7) 39 (4.4) 4228 (6.7) 0.56 (0.40–0.77)
Retired 39 862 (62.5) 647 (72.5) 39 215 (62) 1
Incapacity 3311 (5.2) 51 (5.7) 3260 (5.2) 0.95 (0.71–1.26)
Other 1876 (2.9) 12 (1.3) 1864 (3.3) 0.39 (0.22–0.69)
Weight, kg
,60 8284 (12.9) 113 (12.6) 8171 (12.9) 1 0.98
60–80 27 440 (42.7) 389 (43.3) 27 051 (42.7) 1.04 (0.84–1.28)
.80–100 20 610 (32.1) 288 (32.1) 20 322 (32.1) 1.02 (0.82–1.28)
.100 7869 (12.3) 108 (12.0) 7761 (12.3) 1.01 (0.77–1.31)
Atherothrombotic risk factors
Smoking status
Never 27 016 (43.1) 329 (37.2) 26 687 (43.2) 1 ,0.001
Former 26 177 (41.7) 424 (48.0) 25 753 (41.7) 1.34 (1.16–1.54)
Current 9510 (15.2) 131 (14.8) 9379 (15.2) 1.13 (0.92–1.39)
Diabetes
No 36 287 (56.2) 465 (51.5) 35 822 (56.3) 1 0.004
Yes 28 298 (43.8) 438 (48.5) 27 860 (43.7) 1.21 (1.06–1.38)
High blood pressure
No 11 825 (18.3) 107 (11.8) 11 718 (18.4) 1 ,0.001
Yes 52 759 (81.7) 796 (88.2) 51 963 (81.6) 1.68 (1.37–2.05)
Hypercholesterolaemia
No 18 006 (27.9) 300 (33.3) 17 706 (27.8) 1 ,0.001
Yes 46 512 (72.1) 602 (66.7) 45 910 (72.2) 0.77 (0.67–0.89)
Ischaemic disease
CVD
No 46 696 (72.3) 594 (65.8) 46 102 (72.4) 1 ,0.001
Yes 17 893 (27.7) 309 (34.2) 17 584 (27.6) 1.36 (1.19–1.57)
CAD
No 26 259 (40.7) 345 (38.2) 25 914 (40.7) 1 0.13
Yes 38 330 (59.3) 558 (61.8) 37 772 (59.3) 1.11 (0.97–1.27)
PAD
No 56 737 (87.8) 741 (82.1) 55 996 (87.9) 1 ,0.001
Yes 7852 (12.2) 162 (17.9) 7690 (12.1) 1.59 (1.34–1.89)
Stable angina
No 44 506 (70.0) 590 (66.7) 43 916 (70.1) 1 0.03
Yes 19 041 (30.0) 295 (33.3) 18 746 (29.9) 1.17 (1.02–1.35)
Continued
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Table 1 Continued
Characteristic n (%) Haemorrhage, n (%) OR (95% CI) P-valuea
Yes No
CABG
No 51 117 (79.6) 668 (74.5) 50 449 (79.7) 1 ,0.001
Yes 13 118 (20.4) 229 (25.5) 12 889 (20.3) 1.34 (1.15–1.56)
Current or previous medical conditions
Atrial fibrillation
No 56 471 (89.3) 714 (80.1) 55 757 (89.5) 1 ,0.001
Yes 6743 (10.7) 177 (19.9) 6566 (10.5) 2.11 (1.78–2.49)
CHF
No 54 561 (86.1) 665 (74.7) 53 896 (86.3) 1 0.001
Yes 8782 (13.9) 225 (25.3) 8557 (13.7) 2.13 (1.83–2.48)
Carotid surgery
No 60 992 (95.5) 839 (93.7) 60 153 (95.5) 1 0.01
Yes 2868 (4.5) 56 (6.3) 2812 (4.5) 1.43 (1.09–1.88)
Current chronic therapy
Anticoagulants
No 54 875 (87.7) 669 (76.1) 54 206 (87.9) 1 ,0.001
Yes 7662 (12.3) 210 (23.9) 7452 (12.1) 2.28 (1.95–2.67)
Antiplatelet agents
None 13 725 (21.3) 195 (21.6) 13 530 (21.3) 1 ,0.001
Acetylsalicylic acid 34 939 (54.2) 425 (47.1) 34 514 (54.3) 0.85 (0.72–1.01)
Other antiplatelet 7401 (11.5) 116 (12.9) 7285 (11.5) 1.10 (0.88–1.39)
Both 8412 (13.0) 166 (18.4) 8246 (13.0) 1.40 (1.13–1.72)
Diuretics
No 38 447 (59.8) 447 (49.7) 38 000 (59.9) 1 ,0.001
Yes 25 876 (40.2) 452 (50.3) 25 424 (40.1) 1.51 (1.32–1.72)
Biochemistry
Serum creatinine, mg/dL 1.1+0.7b 1.3+0.8b 1.1+0.7b 1.13 (1.08–1.18)c ,0.001
CABG, coronary artery bypass graft; CAD, coronary arterial disease; CHF, congestive heart failure; CI, confidence interval; CVD, cardiovascular disease; OR, odds ratio; PAD,
peripheral arterial disease; SD, standard deviation.
aGlobal P for each category; univariate analysis.
bMean+ SD.
cPer 1 SD.
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Table 2 Characteristics of the composite outcome
Composite outcome n (%) Bleeding leading to
both hospitalization
and transfusion
Non-fatal
haemorrhagic
stroke
n (%)
Missing 852 (1.3) Missing Missing 852 (100)
No 63 686 (98.6) Missing No 216 (0.3)
No Missing 48 (0.1)
No No 63 422 (99.6)
Yes 903 (1.4) Missing Yes 2 (0.2)
No Yes 118 (13.1)
Yes Missing 1 (0.1)
Yes No 775 (85.8)
Yes Yes 7 (0.8)
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The Hosmer–Lemeshow test for goodness of fit was not statistically
significant (P ¼ 0.432), which is in accordance with an acceptable
calibration.
The final bleeding risk score sheet (Table 3) contained one
demographic factor (age, 2–6 points); two predictors related to
medical history (PAD, 1 point; CHF, 2 points); four comorbidities
or lifestyle characteristics (diabetes, 1; hypercholesterolaemia, 1;
hypertension, 2; smoking 1–2 points); and two medication regi-
mens (antiplatelets, 1–4; oral anticoagulants, 4 points). The
maximum possible score is 23, although the maximum observed
score was 21. This score very closely approximated the complete
nine-factor regression model, with a correlation of 0.993 between
the predicted probabilities from the regression and score.
Risk stratification using our score was quite effective in classify-
ing the risk level of patients, with a more than six-fold increase in
risk between the highest and lowest quartiles: a 2 year incidence of
0.46% in patients with a score of 6 vs. 2.76% in patients with a
score of 11 (Figure 1).
External validation
In the CHARISMA population, 487 (3.1%) severe bleeding events
were recorded. The discrimination performance of the bleeding
risk score was quite similar in the CHARISMA and REACH
patient populations (c-statistics 0.64 and 0.68, respectively). The
coefficient of contingency was 2.30. The modified Hosmer–Leme-
show c2 showed a goodness-of-fit (8.25; P ¼ 0.31), indicating very
good calibration, which is illustrated in Figure 2. The distribution
between observed and expected rate was compared using a
Hosmer–Lemeshow x2 test. The P-value was 0.31, which means
the observed and expected event rates can be considered equal.
Clinical application
Using the bleeding risk score sheet, patient information for age,
PAD, CHF, diabetes, hypercholesterolaemia, hypertension,
smoking, antiplatelets, and oral anticoagulants is matched with
the value for each variable, and the assigned number of points
summed. The total is then matched with the estimated 2 year
risk (Figure 1).
Discussion
We have developed and externally validated a risk score for
serious bleeding in outpatients with atherothrombosis receiving a
broad range of antithrombotic therapies. The score is easy to
use and comprises clinical items that can be collected in a few
minutes. This is, to our knowledge, the first score designed to
predict bleeding in stable patients with atherothrombosis. There
are other risk scores to evaluate bleeding risk, but these were
designed for patients with atrial fibrillation on oral anticoagulants,14
for patients with acute coronary syndromes,15 or for patients
undergoing percutaneous coronary intervention.16 In all of these,
Figure 1 Risk stratification using the score (percentages indi-
cate 2 year risk of serious bleeding).
Figure 2 Calibration plots: observed events in the CHARISMA
population vs. events expected using the score.
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Table 3 Bleeding risk score sheet
Factor Points
Age, years 45–54 55–64 65–74 75 þ
0 2 4 6
Peripheral arterial disease No Yes
0 1
Congestive heart failure No Yes
0 2
Diabetes No Yes
0 1
Hypercholesterolaemia No Yes
1 0
Hypertension No Yes
0 2
Smoking Never Former Current
0 1 2
Antiplatelet agents None ASA Other Both
0 1 2 4
Oral anticoagulants No Yes
0 4
ASA, acetylsalicylic acid.
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particularly those in acute hospitalized settings, the patient popu-
lation characteristics and frequency of use of coronary interven-
tions differ markedly from those experienced by stable
outpatients with atherothrombosis. An additional value of the
current score is that it was built using a large contemporary regis-
try population representative of routine clinical practice across
many geographic areas, and may therefore have better external
validity than one derived from the highly selected patient popu-
lations participating in randomized clinical trials.17,18 We showed
a dramatic increase in bleeding risk with a score .10. Therefore
it seems important to weigh the role of antithrombotic strategies
carefully in clinical situations when a patient has a risk score
.10. As expected, antithrombotics were among the factors that
most heavily impact the score (4 points for dual antiplatelet
therapy and oral anticoagulation). Obviously, the risk of bleeding
needs to be evaluated with a parallel assessment of the risk of
thrombosis. Since bleeding and thrombosis share several risk
factors, this clinical dilemma is not easily resolved, and the resulting
choices may vary according to clinical setting. Hypercholesterolae-
mia had an apparent association with reduced bleeding. The exact
pathophysiological mechanisms underlying this putative protection
remain unclear.
Some risk factors for bleeding previously identified in studies of
hospitalized patients were not included in this outpatient score.
For example, creatinine clearance had been eliminated first for
missing data (.5%). However, forcing this factor into the score
did not improve the model’s discriminative performance. Likewise,
the score does not include anthropometric variables. Body mass
index and weight as categories did not demonstrate independent
association with bleeding and were therefore eliminated after uni-
variate analysis. Some other potential risk factors were not col-
lected in the REACH case report form (history of bleeding,
peptic ulcer disease, cancer, baseline platelet count, haematocrit,
etc.) and could not therefore be considered in the model.
Our score has potential uses in several clinical settings. Con-
cerns have been raised about the prolonged risk of DES thrombo-
sis,19 and continuation of dual antiplatelet therapy for up to 12
months with a DES is recommended20 vs. 1 month with a bare-
metal stent. This score could be useful in assessing the
benefit-to-risk ratio of implanting a bare-metal stent or a DES,
by allowing physicians to compare the bleeding risk of dual vs.
single prolonged antiplatelet therapy. It could also be important
to assess bleeding risk when stents have to be placed in patients
who already require chronic anticoagulants. The decision to con-
tinue or stop dual antiplatelet therapy 12 months after implanting
a DES is a critical issue. The Food and Drug Administration (FDA)
recommend that ‘clopidogrel treatment should continue for at
least 12 months in patients with DESs who are at low risk for
bleeding’.21 However, to our knowledge, there is no tool to
assess the risk of bleeding in atherothrombotic patients. This
score could prove very useful in this setting. Likewise, while an
expert consensus recommended the use of proton pump inhibi-
tors in patients at high risk of gastrointestinal bleeding,22 there
are concerns that these agents may reduce the efficacy of clopido-
grel.23 Even if this concern has been mitigated recently by the
results of the COGENT randomized trial (D.L. Bhatt, TCT 2009,
San Francisco, CA, late-breaking trial presentation), evaluating
the risk of bleeding may assist in selecting the best candidates
for gastroprotection.
There are several potential limitations to this analysis that
deserve consideration. The definition of serious bleeding used
for these analyses required either a haemorrhagic stroke or bleed-
ing leading to both hospitalization and transfusion. However, the
level of detail captured in the REACH case report form did not
provide us with precise information about the nature of the bleed-
ing events (location of bleeding, amount of blood loss and transfu-
sion, clinical outcome). While this definition may underestimate
the rate of major bleeding events, since it does not take into
account events such as epidural haematoma or bleeding requiring
hospitalization but no transfusion, the score underwent external
validation using the CHARISMA database and the widely adopted
and more sensitive GUSTO bleeding definition. The data regarding
thienopyridines are limited to those available at the time the study
was conducted and do not therefore include prasugrel. The
exposure to antithrombotics is extrapolated from yearly data col-
lection, but does not incorporate potential interim changes in
medications between the annual visit. Likewise, the international
normalized ratio achieved was not collected, yet impacts on the
frequency and severity of bleeding.
We eliminated 16 variables for missing data; however, none of
these appeared clinically relevant except for serum creatinine.
This variable was therefore forced into the multivariable analysis
(as well as weight) but did not increase the model’s performance.
The c-statistic in the REACH population (0.68) might be con-
sidered low. However, the performance of a score is evaluated
by its discrimination but also by its calibration,24 which was very
good in the external validation. Finally, our c-statistic (0.68) was
very similar to that of adopted bleeding risk scores (0.67 for the
HEMORR2HAGES score;14 0.71 for the CRUSADE bleeding risk
score15) and superior even to that obtained for the Thrombolysis
in Myocardial Infarction (TIMI) risk score (0.65), which has been
widely adopted into clinical practice.25
In conclusion, we have developed a simple bleeding risk score
for use in outpatients. Prospective use of this score may help ident-
ify patients at increased risk of bleeding complications, and assist in
the selection of antithrombotic treatments and in developing strat-
egies to mitigate that risk.
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